Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)

Table 2 Efficacy of PD-1/PD-L1 inhibitors

	n = 19
median number of Cycle (range)	7 (1–70)
Duration of treatment	2.8 months (1 day-32.9 months)
Best response during administration^a	PR 4, SD 12, PD 1, NE 2
Best response including after discontinuation^a	CR 1, PR 5, SD 11, PD 2 (PR → CR 1, SD → PR 2, NE → SD, PD1)

CR complete response, PR partial response, SD stable disease, PD progressive disease, NE not evaluated
^aAccording to RECIST 1.1; Confirmed by a later scan performed at least 4 weeks after initial response was observed

ISSN: 1471-2407